PubRank

American journal of nuclear medicine and molecular imaging (Am J Nucl Med Mol Imaging)

Journal PubWeight™ 178.09‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Cerenkov imaging - a new modality for molecular imaging. 2012 1.57
2 The clinical use of PET with (11)C-acetate. 2011 1.43
3 False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. 2012 1.42
4 Positron emission tomography (PET) imaging with (18)F-based radiotracers. 2011 1.41
5 Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. 2012 1.41
6 The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. 2014 1.23
7 Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. 2013 1.21
8 How to study optimal timing of PET/CT for monitoring of cancer treatment. 2011 1.19
9 Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. 2013 1.15
10 Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. 2014 1.13
11 (18)F-FDG PET in sarcoma treatment response imaging. 2011 1.12
12 Molecular imaging probe development: a chemistry perspective. 2012 1.10
13 Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. 2014 1.02
14 Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. 2011 1.01
15 Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. 2015 0.99
16 Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. 2013 0.98
17 Synthesis and characterization of intrinsically radiolabeled quantum dots for bimodal detection. 2012 0.98
18 (18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. 2011 0.97
19 PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. 2012 0.96
20 In vivo and ex vivo applications of gold nanoparticles for biomedical SERS imagingi. 2012 0.96
21 Current imaging strategies in rheumatoid arthritis. 2012 0.94
22 Design of "smart" probes for optical imaging of apoptosis. 2011 0.94
23 Radiolabelled probes for imaging of atherosclerotic plaques. 2012 0.93
24 Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. 2014 0.92
25 PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. 2014 0.91
26 A comparison of image contrast with (64)Cu-labeled long circulating liposomes and (18)F-FDG in a murine model of mammary carcinoma. 2013 0.90
27 Optical imaging of tumor microenvironment. 2013 0.90
28 Intravascular near-infrared fluorescence molecular imaging of atherosclerosis. 2013 0.90
29 Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. 2013 0.89
30 Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. 2011 0.89
31 Clinical oncologic applications of PET/MRI: a new horizon. 2014 0.89
32 PET radiopharmaceuticals for probing enzymes in the brain. 2013 0.89
33 Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. 2014 0.88
34 [(125)I]FIAU imaging in a preclinical model of lung infection: quantification of bacterial load. 2012 0.88
35 In a "nutshell": intrinsically radio-labeled quantum dots. 2012 0.88
36 Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain. 2013 0.88
37 Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist. 2011 0.87
38 Imaging of Induced Pluripotent Stem Cells: From Cellular Reprogramming to Transplantation. 2011 0.87
39 One-step and one-pot-two-step radiosynthesis of cyclo-RGD-(18)F-aryltrifluoroborate conjugates for functional imaging. 2013 0.87
40 Ready for prime time? Dual tracer PET and SPECT imaging. 2012 0.87
41 Intravenous administration of diazepam significantly reduces brown fat activity on 18F-FDG PET/CT. 2011 0.87
42 PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. 2013 0.87
43 Optimization of the enhanced permeability and retention effect for near-infrared imaging of solid tumors with indocyanine green. 2015 0.86
44 Peptoid and Positron Emission Tomography: an Appealing Combination. 2011 0.86
45 Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. 2013 0.86
46 "Kit like" (18)F labeling method for synthesis of RGD peptide-based PET probes. 2013 0.86
47 The role of PET/CT in decreasing inter-observer variability in treatment planning and evaluation of response for cervical cancer. 2012 0.86
48 Current neuroimaging techniques in Alzheimer's disease and applications in animal models. 2012 0.85
49 Limitations of SRTM, Logan graphical method, and equilibrium analysis for measuring transient dopamine release with [(11)C]raclopride PET. 2013 0.85
50 Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT. 2013 0.85
Next 50